BioCentury
ARTICLE | Company News

Calmune, Crucell deal

November 9, 2009 8:00 AM UTC

Calmune will use its SEBVI technology to generate human mAbs against an undisclosed infectious disease target for Crucell. SEBV1 technology allows high-affinity, fully human antibodies against microbi...